Stevanato Group S.p.A.
STVNHealthcareNASDAQMedical Instruments & Supplies
Scan Results
Daily timeframeStevanato Group S.p.A. engages in the design, production, and distribution of products and processes to provide solutions for biopharma and healthcare industries in Europe, the Middle East, Africa, North America, South. Valued at $5.13B, STVN is a mid-cap name in its sector. It operates through two segments, Biopharmaceutical and Diagnostic Solutions; and Engineering.
Market Cap
$5.13B
Beta
0.76
P/E (TTM)
31.85
P/E (Fwd)
22.35
EPS (TTM)
$0.59
EPS (Fwd)
$0.84
ROE
9.6%
ROA
5.3%
Cash
$112.3M
Total Debt
$450.6M
Free CF
-$57.1M
52W Change
-16.0%
Annual Financials
Cash vs Debt
The company holds $112.3M in cash, though total debt stands at $450.6M. This level of leverage is common in the industry but worth monitoring as interest rate conditions evolve. The company is burning cash, with free cash flow at -$57.1M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. ROE of 9.6% points to decent capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. An ROA of 5.3% suggests reasonable efficiency in deploying the company's asset base. Revenue has grown from $983.7M (2022) to $1.19B (2025), reflecting a 21% increase over the period.
The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. No single metric tells the full story. Reviewing STVN's risk profile alongside its fundamentals and technical indicators provides a more complete picture.